Literature DB >> 7017408

Suppression of aldosterone by cyproheptadine in idiopathic aldosteronism.

M D Gross, R J Grekin, T C Gniadek, J Z Villareal.   

Abstract

To study the role of serotonin in regulating the release of aldosterone, we gave single, oral doses of cyproheptadine, an antiserotoninergic agent, to five normal volunteers with high aldosterone levels secondary to sodium deprivation and to 14 patients with aldosteronism (six with idiopathic aldosteronism due to bilateral adrenal hyperplasia and eight with adrenal adenoma). A diet containing 150 mmol of sodium was given to the patients with spontaneous aldosteronism, and one containing 10 mmol of sodium was given to the normal subjects, for three days before treatment and throughout the study. All subjects received dexamethasone, 2 mg daily. Serum aldosterone was measured with the subject in the recumbent position before cyproheptadine administration and at 30-minute intervals for two hours afterward. Serum aldosterone fell significantly (P less than 0.025) from the basal level in the patients with idiopathic aldosteronism due to hyperplasia. No fall was observed in the normal subjects or in the patients with adenoma. No changes were seen in renin activity, cortisol, sodium, or potassium, in any group after cyproheptadine. Suppression of aldosterone with cyproheptadine suggests a serotonin-mediated aldosterone-stimulating system. Hyperactivity of this system may be the cause of idiopathic aldosteronism associated with adrenal hyperplasia.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7017408     DOI: 10.1056/NEJM198107233050401

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  14 in total

Review 1.  Low-renin hypertension of childhood.

Authors:  J DiMartino-Nardi; M I New
Journal:  Pediatr Nephrol       Date:  1987-01       Impact factor: 3.714

2.  A possible role for intermediate lobe peptides in the pathogenesis of idiopathic aldosteronism.

Authors:  P J Mulrow
Journal:  Trans Am Clin Climatol Assoc       Date:  1984

3.  Lack of effect of cimetidine on the renin-angiotensin-aldosterone system in man.

Authors:  C Barbieri; R Caldara; M Cambielli; W G Rauhe; M Sala
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

4.  Effect of serotonin on plasma aldosterone in man.

Authors:  F Mantero; G Opocher; M Boscaro; D Armanini
Journal:  J Endocrinol Invest       Date:  1982 Mar-Apr       Impact factor: 4.256

5.  Effect of repeated doses of L-5-hydroxytryptophan and carbidopa on prolactin and aldosterone secretion in man.

Authors:  P H Vlasses; H H Rotmensch; B N Swanson; R A Clementi; R K Ferguson
Journal:  J Endocrinol Invest       Date:  1989-02       Impact factor: 4.256

6.  Renal calculi in primary hyperaldosteronism.

Authors:  U M Kabadi
Journal:  Postgrad Med J       Date:  1995-09       Impact factor: 2.401

7.  Plasma immunoreactive gamma melanotropin in patients with idiopathic hyperaldosteronism, aldosterone-producing adenomas, and essential hypertension.

Authors:  G T Griffing; B Berelowitz; M Hudson; R Salzman; J A Manson; S Aurrechia; J C Melby; R C Pedersen; A C Brownie
Journal:  J Clin Invest       Date:  1985-07       Impact factor: 14.808

8.  Effect of the 5-hydroxytryptamine type 2 receptor antagonist, ketanserin, on blood pressure, the renin-angiotensin system and sympatho-adrenal function in patients with essential hypertension.

Authors:  J R Zabludowski; C Zoccali; C G Isles; G D Murray; J I Robertson; G C Inglis; R Fraser; S G Ball
Journal:  Br J Clin Pharmacol       Date:  1984-03       Impact factor: 4.335

Review 9.  Serotonin and the vascular system. Role in health and disease, and implications for therapy.

Authors:  D S Houston; P M Vanhoutte
Journal:  Drugs       Date:  1986-02       Impact factor: 9.546

10.  The effect of a 5-HT antagonist, ketanserin, on blood pressure, the renin-angiotensin system and sympathoadrenal function in normal man.

Authors:  C Zoccali; J R Zabludowski; C G Isles; G D Murray; G C Inglis; J I Robertson; R Fraser; S G Ball
Journal:  Br J Clin Pharmacol       Date:  1983-09       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.